GlobeNewswire by notified

VIRBAC: growth in revenue in the first half of 2022 of +12.0% at comparable exchange rates (+16.4% at real rates), driven by good performance in all areas

Share
KEY FIGURES
Revenue in first half of 2022 -Provisional



€616.4 million
Growth at constant exchange rates
and scope 1




+12.0% including

companion animals +14.2%

food-producing animals +9.9%
Growth at constant
exchange rates



+12.0%

Overall
change




+16.4%


1 Growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year), and excluding change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year.


Quarterly consolidated revenue
Our second-quarter revenue reached €298.3 million, or a +13.5% increase compared to the same period in 2021. At constant exchange rates, growth was +7.8%, driven by good performance in both the companion animals and food producing animals segments, in a context of market slowdown. It should be noted that our actual performance for the quarter was favorably impacted by the appreciation of certain currencies, such as the US dollar, the Indian rupee, the Brazilian real, and the Mexican peso. At area level, our growth is mainly driven by the performance of the United States, particularly in the dental and dermatology ranges and recently launched products range (Clomicalm, Itrafungol, the petfood and the food producing animals range), by that of the Asia-Pacific zone, where India and Australia continue to benefit from a favorable momentum, and finally Latin America, driven by double-digit growth in Brazil and Mexico.


Cumulative consolidated revenue at the end of June
For the first half of the year overall, our revenues were €616.4 million, compared with €529.4 million, representing an overall increase of +16.4% compared with the same period in 2021. Adjusted for the favorable impact of exchange rates, revenue shows growth of +12.0%. This growth benefited in part from a favorable baseline effect representing 1 point of growth in revenue, attributable to new products acquired starting in the second quarter of 2021.

All areas are growing organically at the end of June. It should be noted, however, that double-digit growth in Europe has stalled in the last quarter, due to the slowdown in the market as anticipated in our annual outlook. Thus, the sales in this area increased by +6.8% at real rates (+6.2% at constant rates), thanks mainly to the contribution of the United Kingdom, France and Italy. The area is supported by the strong dynamism of companion animals ranges (in particular petfood, specialties, and vaccines), which compensate for the withdrawal of ranges intended for food producing animals. In Asia-Pacific, the development at real rates is +19.8% (+15% at constant exchange rates). Australia and India are driving growth in the region, generating more than 85% of the latter, in particular on products destined for cattle, which makes it possible to largely compensate for the withdrawal of China, which was heavily impacted by lockdowns at the beginning of the year and which, despite a rebound since May, remains down at the end of June. In Latin America, activity grew by +25.1% at real rates (+14.6% at constant exchange rates), thanks in particular to contributions from Brazil and Mexico. Finally, in the United States, activity increased by +32.2% (+19.9% at constant exchange rates). It benefits from sustained sales on new products launched in 2021 (Clomicalm and Itrafungol) and those launched in early 2022 (petfood, and Tulissin for the food producing animals segment), as well as good performance on the dental and dermatology ranges.


In terms of species, revenue in the companion animal segment grew overall by +17.9% at real rates (+14.2% at constant exchange rates), mainly driven by very good double-digit growth in the petfood, specialty, dermatology and hygiene ranges, as well as vaccines for dogs and cats. The food producing animals segment also showed strong growth of +15.0% at real rates (+9.9% at constant exchange rates), mainly driven by the ruminant sector (+14.2% at constant exchange rates); and the aquaculture segment (+5.1% at constant rates) compared to the same period in 2021.

Covid-19 health crisis and the war in Ukraine
We continue to face significant production, logistical and supply constraints with regard to certain intermediaries, and more recently, significant inflationary impacts on our costs (energy, raw materials, transportation, etc.).


Outlook
The activity in the first half of the year reinforces our perspective. Revenue growth at constant rates and scope should be in the range of 5% to 10%. The ratio of “current operating profit before depreciation of assets arising from acquisitions” to “revenue” should be around 15% at constant exchange rates, despite the inflationary impacts (with a deliberate overinvestment in R&D of approximately 1 percentage point of revenue compared to 2021). Finally, our debt relief should be around €60 million, excluding dividends, at constant scope and exchange rates.


CONSOLIDATED FIGURES
Non-audited figures 
in millions of euros
20222021GrowthGrowth 
at constant exchange rates 1
Growth 
at constant exchange rates and scope 1
First quarter revenue318.1266.5+19.3%+16.2%+16.2%
Second quarter revenue298.3262.9+13.5%+7.8%+7.8%
Revenue for first half year616.4529.4+16.4%+12.0%+12.0%





A lifelong commitment to animal health

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and to shaping the future of animal health together.

Virbac: NYSE Euronext - compartment A – ISIN code: FR0000031577 / MNEMO: VIRP
Financial Affairs Department: tel. 04 92 08 71 32 - email: finances@virbac.com - Website: corporate.virbac.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Notice of Nexstim Plc’s Half-Yearly Report H1 20228.8.2022 09:00:00 CEST | Press release

Companyannouncement,Helsinki,8 August2022at10 AM(EEST) Noticeof NexstimPlc’sHalf-Yearly Report H1 2022 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") will publish its half-yearly report for the six months ended 30 June 2022 on Friday 12 August 2022 at approximately 9:00 am Finnish time. The company will hold two live webinars for media, investors and analysts on Friday 12 August 2022. Mikko Karvinen CEO, and Joonas Juokslahti CFO, will present the financial and operational results followed by a Q&A session. The first live webinar will be in Finnish, and it will take place at 10:30 am EEST. The second live webinar will be in English at 3 pm EEST. Webinardetails: To attend the webinars, please register via the links below. Registered participants will receive more information to their e-mail. Live Webinar in Finnish on 12 August 2022 at 10:30 am (EEST): Sign up here >> Live Webinar in English on 12 August 2022 at 3 pm (EEST): Sign up here >> NEXSTIM PLC Mikko Karvinen, CEO F

Publicering av Nexstim Abp:s halvårsrapport för H1 20228.8.2022 09:00:00 CEST | Pressemelding

Företagsmeddelande,Helsingfors,8augusti2022 kl.10(EEST) Publicering av Nexstim Abp:s halvårsrapport för H1 2022 Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) kommer att meddela sitt halvårsresultat för det gångna halvåret som avslutades den 30 juni 2022, på fredagen den 12 augusti 2022 cirka kl. 9.00 finsk tid. Bolaget ordnar två webbsända möten för analytiker, investerare och medier fredagen 12 augusti 2022. Verkställande direktör Mikko Karvinen och ekonomichef Joonas Juokslahti presenterar det finansiella resultatet och rörelseresultatet verifier deltagarna ges möjlighet att ställa frågor. Den första webbsändningen på finska börjar klockan 10.30 (EEST). Den andra webbsändningen på engelska börjar klockan 15.00 (EEST). Uppgifteromwebbsändningarna: Anmälning till webbsändningarna sker via länkarna nedan. De deltagare som anmält sig får närmare anvisningar per e-post. Webbsänt informationsmöte på finska 12 augusti 2022 klockan 10.30 (EEST): Till anmälan >> Webbsänt info

Sampo plc’s share buybacks 05/08/20228.8.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 08/08/2022 at 08:30 am Sampo plc’s share buybacks 05/08/2022 On 05/08/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,33944.37AQEU14,45644.38CEUX7,48944.42TQEX78,18844.36XHELTOTAL114,47244.37 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 5,603,062 Sampo A shares representing 1.05 per cent of the total number of shares in Sampo plc. Details of ea

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS5.8.2022 16:20:00 CEST | Press release

Bid procedure, 2022-08-09BondsKOMMUNINVEST I SVERIGE: 2602. SE0013745452. 2026-02-04 KOMMUNINVEST I SVERIGE: 2706, SE0016829048, 2027-06-15 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2022-08-09Bid times10.00-11.00Requested volume (corresponding nominal amount)2602: 200 mln SEK +/-100 mln SEK 2706: 200 mln SEK +/-100 mln SEK Highest permitted bid volume (corresponding nominal amount)2602: 200 mln SEK per bid 2706: 200 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2022-08-11Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchases of Bonds via Bid Procedure 2020:3. dated 20 November 2020 (see the Riksbank´s web). Stockholm, 2022-08-05 This i

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS5.8.2022 16:20:00 CEST | Press release

Bid procedure, 2022-08-11BondsSWEDBANK HYPOTEK AB: 197. SE0016828529. 2027-03-17 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 DANSKE HYPOTEK AB: 2612, SE0015987540, 2026-12-16 NORDEA HYPOTEK AB: 5535, SE0013358413, 2025-09-17 Bid date2022-08-11Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)197: 200 mln SEK +/-100 mln SEK 581: 200 mln SEK +/-100 mln SEK 2612: 100 mln SEK +/-50 mln SEK 5535: 150 mln SEK +/-100 mln SEK Highest permitted bid volume (corresponding nominal amount)197: 200 mln SEK per bid 581: 200 mln SEK per bid 2612: 100 mln SEK per bid 5535: 150 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-08-15Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-08-05 This is a translation of the special terms and